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Abstract
Objectives: Objective of this study is to report the results of nurse led hematuria 
clinic service outcome of 2,714 patients.
Subjects and methods: We conducted a retrospective, single center review of 2714 
patients with visible and nonvisible hematuria managed by a well- trained nurse spe-
cialist in a rapid access clinic (RAC) between 2014 and 2020. All patients received 
a full review, flexible cystoscopy performed by a nurse, and ultrasound of urinary 
tracts. After investigations, patients were reassured and discharged or referred for 
rigid cystoscopy, TURBT, and CT urography.
Results: In total, 2714 patients attended the RAC between October 2014 and March 
2020. Of these, 1684 (62%) were males and 1030 (38%) females. The median age 
of patients was 68.3 (IQR 58- 79). Of the 1030 females, 500 (48.5%) presented with 
nonvisible hematuria (NVH), and 530 (51.5%) presented with visible hematuria (VH). 
The median age was 66 (IQR 56- 76). The number of females diagnosed with any form 
of malignancy was 72 (7% of all females). Of the 1684 males, 288 (17.1%) presented 
with NVH, and 1396 (82.9%) presented with VH. The median age was 72 (IQR 59- 81). 
The number of males diagnosed with some form of malignancy was 258 (15.3% of all 
males). Overall, 1926 patients presented with VH and 788 patients presented with 
NVH. After investigations, 290 patients (15.1%) with VH and 40 (5.1%) patients with 
NVH had some form of malignancy. The highest number of malignancies found in VH 
was bladder cancer (n = 222, 11.5%), followed by prostate (n = 28, 1%), renal (n = 23, 
0.8%), UT urothelial (n = 17, 0.6%), gynaecological (n = 7, 0.3%), and gastrointestinal 
(n = 5, 0.2%) cancer. The highest number of pathologies found in NVH was infection 
(n = 44, 5.6%). Cancer detection rate for symptomatic NVH was more than double 
that of asymptomatic NVH, 6.5% versus 3.1%, respectively.
Conclusion: Overall, 15.1% with VH and 5.1% with NVH present with malignancy. 
Nurse- led rapid access hematuria clinic and flexible cystoscopy investigation by 
trained nurse is safe and feasible.
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1  | INTRODUC TION
Hematuria is an indicator for mainly urinary tract malignancy, partic-
ularly bladder cancer but also upper tract, prostate and occasionally 
renal cancer; nevertheless, it presents also in benign urological pa-
thologies such as urinary tract infections (UTI) and renal calculi.1,2 
Various guidelines recommend hematuria investigations depending 
on patient age and risk factors for malignancy; however, there is no 
standardized strategy.2
Hematuria diagnostics commonly include cystoscopy, upper 
tract imaging (ultrasound, computed tomography, intravenous and 
magnetic resonance urography) and on occasion urine cytology 
and novel urinary biomarkers.1,3 Due to costly investigations, the 
economic impact on healthcare organisations of hematuria investi-
gations is significant,4 particularly seen during the recently experi-
enced pandemic with additional resource requirement, when health 
care has been reallocated and redeployed.
The importance of a rapid diagnostic service when investigating 
hematuria has been demonstrated, particularly when considering the 
relationship between hematuria and bladder cancer and other urolog-
ical malignancies.5 It has been shown that early diagnosis, which can 
optimally occur in a rapid diagnostic service, can appreciably improve 
prognosis.5 The national health system (NHS) “two- week wait referral” 
helps alleviate the issues of diagnostic delays.6 Many one- stop hematu-
ria clinics (OSHC) have been established in the UK, which are especially 
useful given the extensive waiting times for out- patient appointments 
and the lengthy system of investigating and diagnosing patients which 
can take up to a number of weeks and multiple hospital visits.7
Alongside the concerns of untimely diagnoses and extensive inves-
tigations lies the issue of the increasing pressure on medical profession-
als to deliver high- quality, timely services despite the lack of growth in 
number of consultants available to deliver that care,8 including the care 
and workload for bladder cancer.9 Therefore, there has been a growth 
in the role of the nurse practitioner. The value of a nurse practitioner to 
target shortages and imbalances has already been demonstrated,10 par-
ticularly in areas such as primary care to allow for comanagement with 
physicians.11 In urology, it has been shown that with adequate training, 
nurse practitioners can provide diagnostic services such as prostate bi-
opsy and flexible cystoscopy with diagnostic yield equivalent to that 
of a consultant urologist.8,9 The aim of this study was to ensure the 
efficacy and safety of nurse- led hematuria clinic, as opposed to a purely 
clinician- led clinic, and to analyze the hematuria clinic outcomes.
2  | METHODS AND MATERIAL S
Two senior urology Clinical nurse specialists carried out the “one- 
stop” hematuria rapid access clinic (RAC). They had received 
appropriate training for clinical assessment of patients and perform-
ing flexible cystoscopy.
The nurse led hematuria RAC was piloted for a year, as an as-
sessment for patients presenting with non- visible haematuria (NVH), 
which incorporated arranging investigations and reviewing their re-
sults. The clinic then developed into assessing patients with visible 
hematuria (VH) alongside a urology registrar, who was responsible 
for reviewing patient results. After undergoing additional training 
to perform digital rectal examinations (DRE) with a consultant at a 
prostate assessment clinic and IRMER training to enable organisa-
tion of scans, the nurse led hematuria clinic was implemented. The 
one stop clinic was then designed as a method to reduce patient 
hospital visits by having all investigations within a single appoint-
ment. Currently, a clinical nurse specialist (CNS) has been managing, 
assessing and reviewing patients at the OSHC for the past 10 years.
Nurse cystoscopist training was as per the then approved rec-
ommendations from BAUS in 2003. The nurse cystoscopist worked 
for a year alongside a registrar and performed nearly 200 flexible 
cystoscopies, prior to being assessed and signed off for independent 
practice by the consultant. For the first year of independent prac-
tice, the CNS was performing surveillance cystoscopies whilst still 
being supervised for diagnostic, biopsies and stent removals. By the 
time of the Nurse Led Rapid Access clinic commencing in 2014, the 
CNS had performed >1000 flexible cystoscopies.
The nurse led RAC is run as part of the urology outpatient 
clinic, in parallel to a consultant clinic, therefore a consultant is 
always available for advice or a second opinion. This also allowed 
for constant maintenance of cystoscopy training. Discharge letters 
are completed by the CNS, with a copy given to the named con-
sultant for review. To ensure safety and credibility of the OSHC, 
a prospective patient database was maintained to avoid misdiag-
noses and complications, the outcomes of which were presented 
periodically to the hospital audit department. The clinic was ap-
proved by the clinical governance committee, with subsequent au-
dits of the data completed after registration by the local hospital 
audit committee.
Between October 2014 and March 2020, 2714 patients were re-
ferred to the weekly hematuria RAC. The hematuria clinic pathway is 
outlined diagrammatically in Figure 1. Patients were referred mostly 
by general practitioners (GPs), but also some by physicians of other 
specialties. Most patients were referred as per the national institute 
for health and care excellence (NICE) 2 week wait guidelines, pub-
lished in 2015, which included referrals for unexplained VH in indi-
viduals 45 years and over or for unexplained NVH in individuals aged 
60 and over.12 Some patients did not meet the NICE referral criteria 
and were referred as per the discretion of the treating physician. All 
patients who attended the RAC were included in this study, as they 
all had hematuria.
K E Y W O R D S
bladder cancer, flexible cystoscopy, hematuria, nurse, prostate cancer, renal cell carcinoma, 
upper tract urothelial cancer
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Upon attending the RAC, patients were first evaluated by 
the CNS, who took a detailed history and examination (general 
physical examination, genital examination and digital rectal ex-
amination). The RAC history proforma included the presenting 
complaint, severity of lower urinary tract symptoms (LUTS), past 
medical history, medications, allergies, smoking history, alcohol 
history and social situation. Patients also had their bloods taken 
(full blood count and renal function tests) and an ultrasound scan 
of the renal tract performed and interpreted by a radiologist or 
sonographer in the urology department, prior to consultation with 
F I G U R E  1   Flow diagram of protocol 
for RAC
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the CNS, who then reviewed the reports. Following the initial gen-
eral assessment, a flexible white light cystoscopy was performed 
by a second CNS.
At this stage, after the history, examination, USS and cystoscopy, 
patients were informed of their outcomes. Some patients were sub-
sequently reassured and discharged, whilst others were listed for 
further investigation, including rigid cystoscopy, CTU and TURBT. 
All pathologies were followed up according to the appropriate local 
guidelines. Patient details and outcomes were entered, prospec-
tively, into a Microsoft Access database and analyzed using the sta-
tistical analysis ToolPak software on Microsoft Excel.
In 2018, 76 randomly selected patients were asked to carry out 
questionnaires, over a period of 6 months, to evaluate patient sat-
isfaction of the OSHC to assess patient experiences with the RAC. 
The hematuria Clinic Questionnaire (HCQ) developed by Osborne 
et al (2013) was utilised. The HCQ was designed to assess patient 
satisfaction with pre- appointment information, interactions with cli-
nicians, waiting times and explanations.13
3  | RESULTS
In total, 2714 patients attended the Rapid Access Haematuria Clinic 
between October 2014 and March 2020. Of these, 1684 (62%) were 
males and 1030 (38%) were females. The median age of patients was 
68.3 years old, with an interquartile range (IQR) of 58- 79 years old. 
Of the 1030 females attending the clinic, 500 (48.5%) presented with 
NVH, and 530 (51.5%) presented with VH, respectively. The median 
age was 66 years old and the IQR 56- 76. The number of females 
diagnosed with some form of malignancy was 72 (7% of all females). 
Of the 1684 males attending the clinic, 288 (17.1%) presented with 
NVH, and 1396 (82.9%) presented with VH. The median age was 
72 years old and the IQR 59- 81. The number of males diagnosed 
with some form of malignancy was 258 (15.3% of all males) (Table 1).
The highest number of patients were aged between 70 and 79. 
There were only 24 patients within the 20- 29 age category and 135 
patients were aged over 90. Malignancy pick rate increased with age; 
patients aged over 90 had the highest proportion of malignancies 
diagnosed in their age group (28.1% of men aged over 90 and 30.8% 
of women aged over 90). There were only 2 cases of malignancy di-
agnosed in patients aged <40 and 4 cases in patients aged 40- 49. A 
higher percentage of males were diagnosed with malignant disease 
in patients aged 50- 89. However, patients aged less than 50, and 
90 and above, had a higher percentage of females diagnosed with 
cancer (Table 2).
Overall, 1926 patients presented with VH and 788 patients 
presented with NVH. Of the 1926 patients with VH, 290 patients 
(15.1%) had some form of malignancy whereas only 40 (5.1%) pa-
tients with NVH had malignancy. The highest number of patholo-
gies found in VH was bladder cancer (n = 222, 11.5%); the highest 
number of pathologies found in NVH was infection (n = 44, 5.6%). 
Overall, most patients with either VH or NVH had bladder cancer 
(n = 248, 9.1%), followed by benign prostatic hyperplasia (n = 246, 
9.1%).
After bladder cancer, prostate cancer was the second most com-
mon malignant finding (n = 28, 1%). There were also 23 renal (0.8%), 
17 UT urothelial (0.6%), 7 gynaecological (0.3%) and 5 gastrointesti-
nal (0.2%) cancers (Table 3).
Table 4 shows the breakdown of bladder cancer by stages. In the 
cases of the bladder cancer, the majority were T1 disease (n = 91, 
36.7%), then Ta disease (n = 87, 35.1%), then T2 disease (n = 40, 
16.1%) and CIS was found in 31 (12.5%) patients. Muscle invasive 
bladder cancer (MIBC) was present in only 3 (0.4%) patients in the 
NVH group. The VH group had the rest of the 42 cases (2.2%).
Patients' smoking status and severity of LUTS was also recorded. 
74.1% of patients with nonmuscle invasive bladder cancer (NMIBC) 
and 68.9% of patients with MIBC were ex or current smokers. Of 
patients with NMIBC, 63.2% had LUTS; comparatively of patients 
with MIBC, 82.2% had LUTS.
TA B L E  1   Patient characteristics, n = 2714
Males Females Total
No., n (%) 1684 (62.0) 1030 (38.0) 2714
NVH, n (%) 288 (36.5) 500 (63.5) 788
• Benign, n (%) 259 (34.6) 489 (65.4) 748
• Malignant, n (%) 29 (72.5) 11 (27.5) 40
VH, n (%) 1396 (72.5) 530 (27.5) 1926
• Benign, n (%) 1167 (71.3) 469 (28.7) 1636
• Malignant, n (%) 229 (79.0) 61 (21.0) 290
Mean age 69.7 66.1 68.3
Median age 72 66 70
IQR 59- 81 56- 76 58- 79
Smoking history
• Non- smoker, n 
(%)
645 (53.7) 556 (46.3) 1201
• Current smoker, 
n (%)
255 (45.9) 301 (54.1) 556
• Previous smoker, 
n (%)
703 (83.3) 141 (16.7) 844
• Unknown, n (%) 81 (71.7) 32 (28.3) 113
Age ranges
20- 29, n (%) 13 (54.2) 11 (45.8) 24
30- 39, n (%) 57 (64.8) 31 (35.2) 88
40- 49, n (%) 102 (56.4) 79 (43.6) 181
50- 59, n (%) 253 (54.4) 212 (45.6) 465
60- 69, n (%) 296 (54.3) 249 (45.7) 545
70- 79, n (%) 486 (65.5) 256 (34.5) 742
80- 89, n (%) 381 (71.3) 153 (28.7) 534
90+, n (%) 96 (71.1) 39 (28.9) 135
Note: Numbers in parentheses are % of male and female within each 
subgroup.
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We did look further into the VH group and found that 1177 
(61.1%) were symptomatic (s- VH) and 749 (38.9%) were asymptom-
atic VH (a- VH), respectively. Overall, 185 (15.7%) patients with s- VH 
were diagnosed with malignancy and 105 (14%) with a- VH were 
diagnosed with malignancy. Therefore, the cancer detection rates 
were similar in both groups. The age group with most cancers de-
tected was the 90 years and above age group for s- VH (35.4%) but 
was 80- 89 years for a- VH (23.6%); however, there were reasonably 
high cancer detection rates in all ages above 70 years (Figures 2 and 
3). Only 4 cancers were detected in patients younger than 50 years, 
but 3 of these were patients presenting with a- VH; these patients 
were diagnosed with NMIBC.
In the NVH group, 465 (59%) patients presented with symptom-
atic NVH (s- NVH) and 323 (41%) with asymptomatic NVH (a- NVH). 
In the s- NVH group, 30 (6.5%) patients were diagnosed with malig-
nancy and in the a- NVH group, 10 (3.1%) were diagnosed with ma-
lignancy. Therefore, the cancer detection rate for s- NVH was more 
than double that of a- NVH (6.5% vs. 3.1%). The majority of cancers 
were detected in patients aged 80 or above for both s- NVH and 
 a- NVH (Figures 4 and 5). Only 2 cancers were detected in patients 
younger than 50 years; neither of these were urological cancers.
Overall, 1606 (59.2%) patients were discharged or were with-
out pathological findings. Patients with a- NVH had the highest dis-
charge rate at 83.9% and the lowest for s- VH at 51.6%.
Of the 2714 patients in attendance, 2432 completed the full 
workup, approximately 90% of patients. The reasons for not all pa-
tients completing the full work up are varied, including but not lim-
ited to, patient refusal, cancellation or being too unwell to carry out 
all investigations on the day of the clinic. When evaluating outcomes 
of the flexible cystoscopy, 241 patients were identified as having le-
sions. For those patients who were identified as having lesions in 
the flexible cystoscopy on the day of the clinic, 191 patients were 
confirmed as having bladder cancer (a PPV of 79%).
Closer inspection of the database allowed duplicate and repeat 
patients to be retrieved. Of the 2,714 patients attending the RAC, 
a total of 92 patients had to return to the hematuria clinic. The 
Bladder 
cancer stage Frequency VH, n (%) NVH, n (%) Males, n (%) Females, n (%)
Tis/T0 7 6 (85.7) 1 (14.3) 7 (100.0) 0 (0.0)
Ta 87 74 (85.1) 13 (14.9) 60 (69.0) 27 (31.0)
T1 91 83 (91.2) 8 (8.8) 73 (80.2) 18 (19.8)
T2 40 37 (92.5) 3 (7.5) 31 (77.5) 9 (22.5)
T3/4 5 5 (100.0) 0 (0.0) 4 (80.0) 1 (20.0)
+ CIS 31 27 (87.1) 4 (12.9) 27 (87.1) 4 (12.9)
Unfit for 
TURBT
10 9 (90.0) 1 (10.0) 8 (80.0) 2 (20.0)
Unknown 8 7 (87.5) 1 (12.5) 7 (87.5) 1 (12.5)
TA B L E  4   Breakdown of bladder cancer 
T stages; divided into patients of each 
gender, with either VH or NVH
F I G U R E  2   Percentages of patients presenting with symptomatic 
VH, discharged or diagnosed with malignancy
F I G U R E  3   Percentages of patients presenting with 
asymptomatic VH, discharged or diagnosed with malignancy
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majority of these patients were either discharged or were found to 
have the same pathology as when initially investigated. 5 patients 
were found to have malignancy upon return. In one of these cases, 
the patient had initially cancelled further investigations, and so was 
a returning patient to complete the hematuria workup (pT2 bladder 
TCC +CIS). In two of the cases, there was a 3- year gap between the 
initial and return visit (both prostate cancer). One patient returned 
one year later with pTa bladder TCC +CIS, and the final case was of 
a NVH patient returning with VH a few months later and found to 
have a small renal mass on CT.
Patient satisfaction questionnaires yielded a total of 1074 of 
1292 possible responses. The HCQ consisted of a Likert scale, com-
posed “Strongly agree”, “Agree”, “Disagree” and “Strongly disagree” 
options. Patients had an overwhelmingly positive experience at the 
RAC, with 1031 (96.0%) responses indicating “Strongly Agree” or 
“Agree”. As regards the role of nurse practitioner in the hematuria 
clinic, responses were generally positive (100% “Strongly Agree” or 
“Agree”). Most negative responses were in relation to waiting times 
for ultrasound and flexible cystoscopy on the day of OSHC (8% and 
14% of answers indicated were “Disagree” and “Strongly Disagree”), 
with minimal dissatisfaction for the nurse- led aspect of the clinic.
4  | DISCUSSION
The results of this retrospective study are representative of current 
expectations regarding hematuria and the diagnoses following a 
presentation of either NVH or VH, ultimately underlining the safety 
and efficacy of a nurse- led hematuria clinic. Literature shows that 
the presence of VH is a far greater risk factor for urological malignan-
cies than NVH with the estimated detection rates of genitourinary 
cancer in patients presenting with VH and NVH of 13.2%– 24.2% 
and 1.2%– 9.4% respectively.6,14- 17 This is comparable to our cancer 
detection rates at 15.1% and 5.1% for VH and NVH, respectively. 
Up to 60% of patients who are investigated for hematuria in differ-
ent countries will have no identifiable cause18; comparatively, our 
study found that 59.2% of patients were able to be reassured and 
discharged or had no pathological findings, without requiring further 
intervention by a doctor. Direct consultant supervision in the clinic 
is therefore not required in order to safely investigate patients. A 
one- stop nurse- led hematuria clinic allows for efficient management 
of patients, especially given that the prevalence of hematuria is 5%– 
20%.14 Increasing workloads mean that any opportunity to increase 
timely diagnostic investigations, whilst maintaining safe standards 
and patient satisfaction, is very much welcomed.
Visible hematuria is the commonest reason for hematuria refer-
ral to secondary care from primary care centers. More malignancy 
is associated with visible hematuria than non- visible hematuria. Our 
results showed that bladder cancer is the commonest malignancy 
associated with visible hematuria. Bladder cancer in our study was 
3.5 times more likely to be found with VH (11.5%) than NVH (3.3%), 
which is consistent with the findings in the literature. Muscle inva-
sive bladder cancer is very rare to present as a non- visible hematuria 
and out of all the bladder cancer cases in our study, only 3 patients 
with muscle invasive bladder cancer presented with NVH (<1%). 
Malignancies diagnosed were not limited to bladder or renal cancer, 
but also included prostate, gynaecological and gastrointestinal can-
cer. Smoking is the commonest risk factor associated with bladder 
cancer as 71% of the patients with bladder cancer were current or 
Ex- Smokers.
In non- visible hematuria, the detection of malignancy has dif-
ferent variations, in bladder cancer it ranges from 0%– 16%, renal 
cancer detection ranges from 0%– 9.7% and UTUC ranges from 
0%– 3.5%.19 In the present study, bladder cancer was present in 
3.3% of patients with NVH, renal cancer in 0.4% and UTUC in 
0.3%. It has been questioned whether investigation of NVH is 
F I G U R E  4   Percentages of patients presenting with symptomatic 
NVH, discharged or diagnosed with malignancy
F I G U R E  5   Percentages of patients presenting with 
asymptomatic NVH, discharged or diagnosed with malignancy
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clinically relevant due to the lack of clinical significance of NVH, 
particularly when asymptomatic.20 Out of all asymptomatic NVH, 
ten patients (3.1%) were found to have malignancies, which could 
easily have been missed; out of these, seven were cases of bladder 
cancer. The costs for diagnosing and treating patients with inva-
sive bladder or renal cancer is six times that of localised disease, 
highlighting the importance of early recognition of malignancy 
with hematuria.6
The overall ratio of male to female harbouring malignancy in 
our results was approximately 2:1. Visible hematuria represents 
the majority of the referrals in our study (71%). Urological malig-
nancies are uncommon in young age as our data showed that from 
any of the 2714 patients, malignancy did not occur in the group 
of patients <30 years old and only two patients in the age group 
<40 years were diagnosed with malignancy. There were many pa-
tients included in the study, who attended the hematuria clinic, 
that did not meet the NICE guidelines for two- week referral.12 
However, had all the patients been referred as according to the 
guidelines, there would be at least seven patients whose malig-
nancies may have been undiagnosed. It is also important to note 
that a significant finding may mean something different to the pa-
tient than it does to the clinician; it has been demonstrated that 
most patients would want cancer investigations when the chance 
of a cancer diagnosis is as low as 1%.21 However, the current NICE 
guidelines, developed in 2015, used a cancer detection rate of 
3% as the basis for the referral recommendations for a suspected 
cancer diagnosis.22 Hematuria, however, is not only specific to 
cancers and can occur in other pathologies which have severe 
consequences if left undiagnosed, including bladder diverticula, 
kidney calculi and strictures. This highlights the importance of the 
clinic in diagnosing a wide variety of conditions. It has been eval-
uated that in the United Kingdom (UK), the commonest causes of 
hematuria are bladder cancer, UTIs, urolithiasis, benign prostatic 
enlargement and nephrological diseases.18 This is similar with our 
findings where bladder cancer was the most prevalent (9.1%), fol-
lowed by BPH (9.1%), and calculi (8.3%).
Currently urine cytology is not performed as a routine test in 
our hematuria clinic as evidence from the literature currently didn't 
recommend use of urine cytology routinely in investigating hematu-
ria but can be used in selected cases.23 Urine cytology can be per-
formed as part of the surveillance for bladder cancer high risk group 
of patients.12
All the patients were seen within two weeks of referral as per 
the NICE guidelines. This study highlights the usefulness of OSHC 
and the importance of a nurse practitioner in managing it. Allowing 
patients to be seen in one clinic reduces overall hospital atten-
dance. Osborne et al13 evaluated the outcomes of a one- stop visible 
hematuria clinic (OSMC) for the first 100 patients in New Zealand 
and found that it had an 81% compliance rate and high patient sat-
isfaction, indicating the value of the nurse- led clinic. Ooi et al16 
also reported the value of the nurse practitioner (NP); however, Ooi 
et al suggested the usefulness of having an experienced urology 
nurse working as part of the one- stop clinic as the NPs worked 
under direct supervision of the urologist. The present study can 
also provide insights into the patient experience. Following evalu-
ation of patient satisfaction with questionnaires, we demonstrated 
a high level of satisfaction from all areas of the OSHC, analogous 
with the findings of Osborne et al.13 We can assume that the thor-
ough investigations over the course of the day can help put pa-
tients' minds at rest, as inevitably, the finding of blood in urine can 
be a distressing experience. This should be taken into consideration 
for anyone starting their own clinic. Further considerations include 
adequate training of the nurse cystoscopist to carry out cystos-
copies, as well as sufficient experience in diagnostic cystoscopy 
before working in the RAC; adequate training of the CNS running 
the clinic and performing a review and examination of the patient. 
Experience can be gained through other, similar clinics such as a 
LUTS clinic. And finally, ensuring the OSHC is running parallel to a 
consultant- led clinic to allow for the availability of supervision and 
guidance at all times.
Limitations of this study include the incompleteness of our data. 
Patients were not followed up through their entire patient journey, 
so some facts are still unknown such as treatment and survival data. 
Furthermore, patients that were discharged from the hematuria 
clinic may have had to be followed up for other pathologies however 
this long- term follow up data was not recorded. The RAC proforma 
was limited; data on significant risk factors such as BMI, dietary hab-
its etc was not collected. Some data was undocumented in the da-
tabase such as drug history and past medical history which may also 
provide key insights into the significance of malignancies detected. 
It is also important to acknowledge that the data represents patients 
from a single hospital and so our findings may not be generalisable 
to the wider community. Though the majority of patients underwent 
some form of imaging (primarily US) and flexible cystoscopy on the 
same day, we acknowledge that not every patient underwent all 
testing including a CT as well, due to external factors such as patient 
preference, scheduling issues and other unknown reasons. Although 
many patients were referred as per the NICE guidelines for urgent 
referrals, many patients were also referred that did not meet the 
NICE guidelines. Finally, a formal economic evaluation has not been 
covered by the present study.
In conclusion, this study provides a unique evaluation of a large 
volume of prospective data from a hematuria rapid access clinic. Our 
results validate previous studies conducted on the OSHC, particu-
larly malignancy and significant urological pathology detection rates. 
Therefore, a Nurse led hematuria clinic is feasible and can be safely 
performed by nurses following the appropriate training with analo-
gous outcomes to the literature.
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